5 big analyst AI moves: Apple lifted to Buy, AI chip bets reassessed
Investing.com - Piper Sandler has reiterated an Overweight rating and $75.00 price target on Upstream Bio (NASDAQ:UPB), maintaining its positive outlook on the biopharmaceutical company. According to InvestingPro data, analyst targets range from $35 to $75, with a strong consensus recommendation of 1.4 (where 1.0 is a Strong Buy).
The research firm noted that UPB stock has traded up precisely 138.84% over the last six months following promising efficacy and safety results from the Phase 2 VIBRANT trial for verekitug, the company’s TSLP-R monoclonal antibody treatment for chronic rhinosinusitis with nasal polyps (CRSwNP). With a current market capitalization of $1.13 billion, InvestingPro analysis suggests the stock is trading above its Fair Value.
Piper Sandler expressed bullishness ahead of the upcoming Phase 2 VALIANT severe asthma topline results, expected in the first quarter of 2026, citing that targeting the TSLP receptor has clear biological rationale and is de-risked by the Phase 2 VIBRANT results. InvestingPro data reveals the company maintains a strong financial position with more cash than debt and a healthy current ratio of 38.27, though investors should note that analysts expect net income to decline this year.
The firm believes verekitug has a high probability of success to achieve a placebo-adjusted 50% reduction in annualized asthma exacerbation rate (AAER) at a quarterly dosing schedule, which Upstream Bio has indicated would be sufficient to differentiate the treatment in the biologic landscape.
Piper Sandler sees significant value potential for verekitug, highlighting its efficient mechanism of action and clean safety profile that could offer patients a convenient and effective therapeutic across respiratory diseases with blockbuster potential.
In other recent news, Alnylam Pharmaceuticals has seen its stock price target increased to $535 from $459 by Truist Securities, which continues to maintain a Buy rating. This adjustment is driven by heightened third-quarter Amvuttra sales projections, with analyst estimates suggesting U.S. sales could reach approximately $550 million. Truist Securities anticipates that Alnylam will deliver strong earnings for Q3 2025, although they caution that the risk/reward profile may be negatively skewed due to the stock’s substantial performance this year.
Meanwhile, Upstream Bio has garnered attention from several analyst firms. Truist Securities initiated coverage with a Buy rating and a $47.00 price target, highlighting the potential of its TSLP-receptor inhibitor, verekitug, in the inflammatory and immunology respiratory disease market. Piper Sandler reiterated its Overweight rating and a $75.00 price target, noting the stock’s significant momentum. Additionally, JPMorgan maintained its Overweight rating and a $35.00 price target, expecting positive Phase 2 trial results for verekitug in the coming months. These developments underscore the growing interest in Upstream Bio’s potential in the biopharmaceutical sector.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.